Table 2.
DGEL According to the Presence or Absence of Relevant Clinical or Morphologic Characteristics in Human Patients and According to the Group in Mice.
| Characteristic (n)a | DGEL | ||
|---|---|---|---|
| Human patients | Absence | Presence | p |
| Type 2 diabetes (12) | 63.1±16 | 64.7±15.2 | .79 |
| High blood pressure (6) | 66.0±14 | 51.2±16.1 | .08 |
| Obesity (9) | 59.1±17 | 66.2±14.9 | .27 |
| Steatosisb (14) | 55.0±15.5 | 71.0±14.6 | .02c |
| Liver inflammationd (12) | 62.7±17.0 | 60.6±13.9 | .76 |
| Atherosclerosise(15) | 60.0±14.1 | 72.9±14.0 | .03c |
| Age above 50 years (12) | 65.7±11.0 | 60.7±21.8 | .43 |
| MSf (9) | 63.3±15.3 | 65.3±17.7 | .78 |
| Mouse model group | Control | NAFLD | |
| 12.3±8.2 | 32.2±14.1 | .000c | |
Note. a(n): Individuals with presence of the characteristic of a total sample of 29 human patients. bSteatosis in more than 20% of the liver tissue. cStatistically significant. dLiver inflammation in 33% or more of the liver tissue. eGrade IV atherosclerosis, or higher. fMetabolic syndrome. DGEL = degree of germinal epithelial loss; MS = metabolic syndrome.